Effect Of Metformin On Global Phosphorylation Profiles Of Primary Skeletal Muscle Cells Derived From Overweight/obese Insulin Resistant Human Participants by Shah, Nishit
Wayne State University
Wayne State University Theses
1-1-2015
Effect Of Metformin On Global Phosphorylation
Profiles Of Primary Skeletal Muscle Cells Derived
From Overweight/obese Insulin Resistant Human
Participants
Nishit Shah
Wayne State University,
Follow this and additional works at: https://digitalcommons.wayne.edu/oa_theses
Part of the Medicinal Chemistry and Pharmaceutics Commons, and the Pharmacology
Commons
This Open Access Thesis is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne
State University Theses by an authorized administrator of DigitalCommons@WayneState.
Recommended Citation
Shah, Nishit, "Effect Of Metformin On Global Phosphorylation Profiles Of Primary Skeletal Muscle Cells Derived From Overweight/
obese Insulin Resistant Human Participants" (2015). Wayne State University Theses. 440.
https://digitalcommons.wayne.edu/oa_theses/440
 
 
EFF
O
ECT OF M
PRIM
VERWEIG
                 
ETFORMIN
ARY SKE
HT/OBES
Su
in pa
                  
 ON GLO
LETAL MU
E INSULIN
NIS
T
bmitted to 
of Wayne 
Detro
rtial fulfillme
for th
MASTER
    
    
         
                
BAL PHOS
SCLE CE
 RESISTA
by 
HIT SHAH
HESIS 
the Gradua
State Univ
it, Michiga
nt of the r
e degree o
 OF SCIE
2015 
MAJOR: 
Approved B
 
Advisor     
PHORYLA
LLS DERIV
NT HUMA
 
te School
ersity, 
n 
equirement
f 
NCE 
PHARMAC
y: 
                
TION PRO
ED FROM
N PARTIC
s 
EUTICAL 
                
FILES OF
 
IPANTS 
SCIENCES
    Date
 
 
 
 
 
© COPYRIGHT BY 
Nishit Shah 
2015 
All Rights Reserved
 
 
ii 
 
DEDICATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
To the World beloved  
 
 
iii 
 
ACKNOWLEDGEMENTS 
  I would like to express my sincere gratitude to my adviser Dr. Zhengping 
Yi for his guidance, encouragement and support throughout my Masters Study 
and research work. I am also very much thankful to my committee members, Dr. 
Anjaneyulu Kowluru and Dr. Kyle Burghardt for their insightful and valuable 
comments for the progress of research. 
I am also very much grateful to Dr. Michael Caruso for his generous help 
and advice for the completion of the project. I would like to thank Dr. Abdullah 
Mallisho for his support during the study. I would like to extend my thanks to Dr. 
Xiangmin Zhang and Dr. Danjun Ma for being supportive in the research and the 
other laboratory members Mr. Yue Qi, Ms. Divyasri Damacharla, Mr. Majed 
Alharbi and Mr. Jake Silbert for their help. 
 At last but not the least, I am very much thankful to my family for being 
supportive and believing in me all the time.   
 
 
iv 
 
TABLE OF CONTENTS 
 
DEDICATION........................................................................................................ ii 
ACKNOWLEDGEMENTS ................................................................................... iii 
LIST OF TABLES ................................................................................................ vi 
LIST OF FIGURES ............................................................................................. vii 
CHAPTER 1 INTRODUCTION ............................................................................. 1 
1.1 DIABETES MELLITUS AND INSULIN .................................................... 1 
1.1.1 TYPES OF DIABETES ...................................................................... 1 
1.1.2 INSULIN SENSITIVITY AND INSULIN RESISTANCE ...................... 2 
1.2 TREATMENT OF DIABETES .................................................................. 3 
1.2.1 METFORMIN AND IT’S RELATED KNOWN FACTS ........................ 5 
1.3 SKELETAL MUSCLE INSULIN RESISTANCE ...................................... 8 
1.4 PHOSPHORYLATION IN INSULIN SIGNALING AND INSULIN 
RESISTANCE ................................................................................................... 9 
1.5 MASS SPECTROMETRY (MS) BASED PROTEOMICS ........................ 9 
CHAPTER 2 RESEARCH DESIGN AND METHODS ........................................ 11 
2.1 MATERIALS .......................................................................................... 11 
2.1.1 REAGENTS ......................................................................................... 11 
2.2 SUBJECTS ............................................................................................ 12 
2.3 HYPERINSULINEMIC-EUGLYCEMIC CLAMP .................................... 12 
2.4 PROTEOMICS EXPERIMENTAL PROCEDURES ............................... 13 
 
 
v 
 
2.4.1 PRIMARY CELL CULTURE ............................................................ 13 
2.4.2 BRADFORD PROTEIN MEASUREMENT ...................................... 15 
2.4.3 PROTEIN DIGESTION .................................................................... 15 
2.4.4 TITANIUM DIOXIDE PHOSPHOPEPTIDE ENRICHMENT ............. 16 
2.4.5 HPLC-ESI-MS/MS ANALYSIS ........................................................ 17 
2.4.6 PHOSPHOPEPTIDE IDENTIFICATION .......................................... 17 
2.4.8 STATISTICAL ANALYSIS ............................................................... 19 
CHAPTER 3 RESULTS ...................................................................................... 20 
CHAPTER 4 DISCUSSION ................................................................................ 21 
CHAPTER 5 CONCLUSION & FUTURE STUDIES ........................................... 28 
REFERENCES ................................................................................................... 57 
ABSTRACT ........................................................................................................ 67 
AUTOBIOGRAPHICAL STATEMENT ............................................................... 69 
 
 
   
 
 
vi 
 
LIST OF TABLES 
Table 1- Clinical characteristics of participants in the phosphorylation of 
metformin study………………………………………………………………………..30  
Table 2- Different conditions and/or treatment of cells………………………….31 
Table 3- Significantly changes phosphor-sites among 6 sets of 
samples…..……………………………………………………………………..…..32-34 
  
 
 
vii 
 
LIST OF FIGURES 
Figure 1- Structure of Metformin…………………………………………………….35 
Figure 2- Possible effects of metformin….…………………………………………36 
Figure 3- Potential action of metformin……………………………………………..37 
Figure 4- Potential action of metformin in glucose production…………………...38 
Figure 5- Describes the different parameters with their range to determine 
diabetes & pre-diabetes ………..…………………………………………………….39 
Figure 6- Hyperinsulinemic-euglycemic clamp …….…………………...…..40 
Figure 7- Euglycemic insulin clamp study………………………………………….41 
Figure 8A- Experimental workflow…………………………………………………..42 
Figure 8B- Sample preparation for proteomics experiments……………………..43 
Figure 9- The statistical analysis of proteomics workflow...………………………44 
Figure 10 to 21B- Shows significant changes for phosphor-sites ….............45-56 
 
 
1 
 
 
 
CHAPTER 1 INTRODUCTION 
1.1 DIABETES MELLITUS AND INSULIN 
Diabetes describes a group of metabolic disorders in which high blood 
glucose  along with relative insulin deficiency is observed with concomitant 
disturbances of carbohydrate, fat, and protein metabolism [1]. In addition to 
hyperglycemia, diabetes contributes to the dysfunction and failure of various 
organs, such as heart and kidney disease [1]. 
1.1.1 TYPES OF DIABETES 
There are three main types of diabetes, type-I, type-II (T2D) and 
gestational diabetes [2]. Type-I and type-II diabetes are also known as Insulin 
Dependent Diabetes Mellitus (IDDM) and Non-Insulin Dependent Diabetes 
Mellitus (NIDDM), respectively [3]. Type-I diabetes is an autoimmune disorder 
that leads to destruction of the insulin producing pancreatic beta cell[2]. Type-II 
diabetes is the most common form of diabetes in which the body cannot properly 
utilize insulin secreted by the pancreas. Type-II diabetes occurs due to insulin 
resistance and relative insulin deficiency [2]. Initially the pancreas produces more 
insulin to compensate for insulin resistance but over time, the beta cells cannot 
produce enough insulin to keep the blood sugar levels within normal range [2]. 
Gestational diabetes occurs in women during the pregnancy. According to a 
2014 analysis by the Center for Disease Control and Prevention, 9.2% of all 
pregnant women face gestational diabetes [2]. The causes behind gestational 
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diabetes is not known but based on some clues, it is believed that the actions of 
hormones from the placenta block insulin action in the mother’s body [2]. 
In the United States 29.1 million Americans had diabetes in 2012, which is 
9.3% of the total population. Among all cases of diabetes, approximately 95% of 
cases were Type-II Diabetes (T2D) in the US [2]. The major reasons behind type-
II diabetes are the include insulin resistance and dysfunction of insulin secretion 
[4]. 
1.1.2 INSULIN SENSITIVITY AND INSULIN RESISTANCE 
Type-II Diabetes is one of the most common increasing diseases at an 
alarming rate of the current era [5]. Insulin resistance is one of the primary 
contributors behind T2D [6]. Insulin is a hormone which is produced by beta cells 
of islets present in the pancreas [7]. Insulin contains two polypeptide chains 
containing 51 amino acids, with a molecular weight of ~6 kDa. The two chains,  A 
and B, have 21 and 30 amino acids, respectively [3].  
Among different mediators for insulin resistance, a key factor is reduced 
capacity of skeletal muscle to oxidize fatty acids and impairs mitochondrial 
function [8]. Fat deposition in skeletal muscle is more than usual in insulin 
resistance. One of the reasons behind it is that less free fatty acid (FFA) 
oxidation by leg tissues is observed in obese people compared to lean people 
[9]. However, the uptake of FFA is more in obese people than lean people which 
simultaneously develop insulin resistance [9]. Different organs, such as the liver, 
possess specific transporters which might be negatively affected in the diabetes 
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state or during obesity [10]. Insulin sensitivity has been shown to be ameliorated 
by acute exercises and/ or physical training in obese people or T2D patients, in 
addition  weight loss also increases insulin sensitivity [11]. 
1.2 TREATMENT OF DIABETES 
In the early stages of T2D, blood sugar levels within range may be 
attained with just diet and exercise. However, most T2D might need oral 
medication or insulin therapy which depends on many factors. Oral medications 
available on the market today, belong to different classes that control the blood 
sugar level with different mechanisms such as by reducing hepatic glucose 
production [12], increase insulin sensitivity [13], increasing glucose absorption 
[12], raising more glucose excretion [14] and stimulating insulin secretion [15]. 
Different classes of oral drugs are available in market today, such as 
Sulfonylureas, Metglitinides, Thiazolidinediones, Alpha-glucosidase inhibitors, 
DPP-4 inhibitors, SGLT2 inhibitors, and Biguanides. 
Sulfonylureas stimulate insulin secretion from pancreatic β-cells through 
inhibition of KATP channels. Sulfonylureas primarily act on closing of KATP 
channels and indirectly cause degranulation of insulin containing secretory 
granules and increase the insulin concentration which is not dependent on blood 
sugar levels [15]. Drugs from the Metglitinides class work similar to the drugs 
from the sulfonylureas class. Metglinides bind on “sulfonylurea receptor” binding 
sites of β-cells in pancreas and stimulate insulin release [16]. Metglitinides do 
have a shorter half-life compared to Sulfonylureas [17]. Thiazolidinediones such 
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as pioglitazone, rosiglitazone, troglitazone, increase insulin sensitivity in muscle 
and fat, and decrease hepatic glucose production [13]. Thiazolidinediones work 
through activation of gamma isoform of the peroxisome proliferator-activated 
receptor (PPAR-γ) [18]. 
Drugs from the alpha-glucosidase inhibitor class do not result in more 
insulin production and also do not result in low blood sugar levels [19]. Alpha-
glucosidase inhibitors help to maintain the blood sugar level within range by 
slowing down the digestion of complex carbohydrates [20]. Drugs from the 
Dipeptidyl Peptidase IV (DPP-4) inhibitor class exert their effect by inhibiting the 
degradation of incretins, glucose-dependent insulinotropic peptide (GIP) and 
glucagon-like peptide-1 (GLP-1) [21].. Sodium-glucose cotransporter 2 (SGLT2), 
present in the proximal tubule of the kidney, is responsible for approximately 90% 
of renal glucose reabsorption. SGLT2 inhibitors lead to more glucose excretion in 
urine [14]. 
In addition to insulin, several injectable anti-diabetic medications have 
been developed, such as Pramlintide, and incretin mimetics (e.g., Exenatide), 
Pramlintide exerts it’s effect by increasing gastric emptying time, decreasing 
glucagon release and also by reducing food intake [22]. Exenatide is a GLP-1 
receptor agonist and exerts its effects through inhibition of food intake and 
glucose-dependent stimulation of insulin secretion [23]. 
Biguanides (such as metformin, phenformin) act by increasing glucose 
absorption, insulin secretion, and by reducing hepatic glucose production but no 
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clear mechanism how biguanides work is yet completely understood [12]. 
Metformin is the first line of drug to treat T2D and ~30% of T2D patients are 
taking metformin [24]. Apart from T2D, metformin is useful for cancer treatment, 
gestational diabetes, and for prevention of T2D in pre-diabetic population [24]. 
Metformin is still under investigation for its potential anti-neoplastic activity and 
has been observed to reduce cardiac ischemia/ reperfusion injury [25]. Early 
treatment with metformin in rats in adolescence shows inhibition of tumor growth 
[26]. 
1.2.1 METFORMIN AND IT’S RELATED KNOWN FACTS 
Chemical Formula: C4H11N5  
IUPAC Name: 3-(diaminomethylidene)-1,1-dimethylguanidine 
 Metformin’s sugar lowering action was first discovered in 1929 by Slotta 
and Tschesche in rabbits but it was forgotten because its other analogues 
became popular [27]. In 1950, more research on metformin took place and after 
passing through clinical trials, it became available on market only in the UK in 
1958. Later, metformin was approved by Canada in 1972 and by US-FDA in 
1994 [28]. The structure of metformin is shown in Figure 1. 
 Metformin is absorbed slowly when given orally and has 50-60% of 
bioavailability under fasting conditions [29]. The elimination half-life of metformin 
is around 6 hours in plasma and 18 hours in red blood cells [29]. Metformin exists 
in its cationic form at physiological pH as it has acid dissociation constant values 
(pKa) of 2.8 and 11.5 [29]. 
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Metformin has an effect on different tissues and/or organs such as skeletal 
muscle, adipose tissue, liver and kidney [24]. Multiple mechanisms might be 
involved individually or in combination [25]. 
 The marked effect of metformin is that it decreases hepatic glucose 
production through inhibition of the mitochondrial respiratory-chain complex 1 
[24]. Some research studies have suggested that the primary action of metformin 
is through activation of the AMP-activated protein kinase (AMPK) pathway [30]. 
Recent studies suggest that the primary effect of metformin is on the respiratory 
chain complex-1 instead of AMPK [24]. However, the molecular interactions 
between metformin and mitochondrial respiratory chain complex 1 are still not 
clear. Additional mechanisms include inhibition of adenylate cyclase in response 
to energetic stress, and the direct inhibition of mitochondrial glycerophosphate 
dehydrogenase. The above mechanisms might be involved individually or in 
combination [25]. Metformin activates the AMPK pathway in skeletal muscle 
which increases glucose uptake through SLC2A4 (Solute Carrier Family 2 
(Facilitated Glucose Transporter), Member 4) [31]. Some research studies also 
suggested reduced activity of NADH:O2 oxidoreductase when skeletal muscle 
tissue is treated with metformin [32]. 
Additionally, the major effect of metformin or any other drugs from the 
biguanide class is inhibition of glucose production through glucagon signaling 
rather than glucose uptake by activated AMPK [33]. Glucagon signaling in the 
liver is responsible for hepatic glucose production. Events such as activation of 
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adenylyl cyclase, production of second-messenger cyclic AMP (cAMP) and 
stimulation of protein kinase A (PKA) take place, when glucagon binds to its 
receptors on the hepatocyte plasma membrane. Stimulation of PKA further 
phosphorylates protein targets which increase or support the hepatic glucose 
production [33]. Metformin or any other biguanide drug reduces production of 
cAMP by inactivating adenylyl cyclase which further results in termination of 
stimulation and phosphorylation of PKA and related target proteins, respectively. 
Figure 4 shows a flow of how metformin reduces glucose production in liver. It is 
also suggested that metformin disrupts respiratory chain complex-I in 
mitochondria which results in reduction of hepatic glucose output and activation 
of AMPK pathway [34]. 
Metformin uptake in cells appears through Organic Cationic Receptor 
(OCT) 1, 2 and 3 [35]. Metformin occurs in its cationic form at physiological pH. 
Accumulation of metformin has been observed in mitochondria which results in 
change of membrane potential. Aggregation of positively charged metformin acts 
as hydrophobic inhibitors of complex-1 [36]. An increase in AMP/ATP ratio has 
been observed as a resulting effect of inhibition of complex-1 which further 
supports phosphorylation of AMPK. 
Due to inhibition of the mitochondrial respiratory chain complex-1, 
ATP/AMP ratio decreases which supports the activation of AMPK. However, few 
studies suggest that activation of AMPK is not because of energy change related 
to inhibition of respiratory chain complex-1 [30]. AMPK is composed of three 
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different subunits called alpha, beta and gamma. Among the three subunits, the 
alpha subunit is a catalytic unit of AMPK and the regulatory site (Thr-172) on the 
catalytic alpha subunit of AMPK has been stimulated through phosphorylation by 
metformin in intact cells [30]. Metformin treated cells have shown more AMPK 
activity. AMPK is activated without any changes in the ADP-to-ATP ratio when 
treated with metformin in Chinese Hamster Ovary (CHO) cells and the rat 
hepatoma cells (H4IIE) [30]. 
1.3 SKELETAL MUSCLE INSULIN RESISTANCE 
Insulin stimulates glucose uptake in different organs and tissues in the 
body such as adipose tissue, and skeletal muscle. Skeletal muscle is the major 
site of glucose disposal and skeletal muscle insulin resistance is considered a 
primary metabolic defect in the pathogenesis of type 2 diabetes (T2D) [37, 38]. It 
has been shown that under the hyperinsulinemic euglycemic clamp condition, 
glucose uptake between T2D patients and non-diabetic controls is not different in 
liver, brain and adipose tissue but is markedly reduced in skeletal muscle. Figure 
7 describes the observed decrease in glucose uptake in skeletal muscle 
compared to liver, brain and adipose tissue. 
There are several methods available clinically to determine insulin 
sensitivity or insulin resistance, such as Insulin Tolerance Test (ITT), 
Hyperglycemic Clamp, the Insulin Modified frequently Sampled Intravenous 
Glucose Tolerance Test (FSGIT), the Oral Glucose Tolerance Test (OGTT), 
Fasting Surrogates, and the Hyperinsulinemic-Euglycemic Clamp. All the 
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methods have their importance and validity but Hyperinsulinemic-Euglycemic 
Clamp to determine insulin sensitivity is considered as the golden standard  [39]. 
1.4 PHOSPHORYLATION IN INSULIN SIGNALING AND INSULIN 
RESISTANCE 
Reversible phosphorylation plays a fundamental role in insulin signaling 
[37, 40]. Abnormal phosphorylation of insulin signaling proteins, such as the 
insulin receptor and insulin receptor substrate 1, in skeletal muscle is 
reproducibly observed in T2D [37, 40]. Nonetheless, most studies on 
phosphorylation-mediated signaling in T2D are focused on a few down targets. 
1.5 MASS SPECTROMETRY (MS) BASED PROTEOMICS 
Many research projects today involve extremely complex mixtures, which 
increases the demand for instruments with better performance characteristics 
such as high sensitivity, mass accuracy, resolution, reproducibility [41].  Mass 
spectrometry has emerged as one of the best approaches for proteomics [42] 
due to recent development of mass spectrometer with high sensitivity, mass 
accuracy, resolution, reproducibility (such as Orbitrap) [43]. 
Emerging as a key technology in exploring signal-transduction, quantitative 
phosphoproteomics has mapped many differential phosphorylation events in 
signaling networks and cascades [44-46]. Phosphoproteome studies have 
generated valuable data, which are unattainable by genomics and 
transcriptomics studies, and provided insights into molecular mechanisms of 
various disease pathogenesis, and aided in the discovery of drug targets for 
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disease treatment [44-46]. Nonetheless, no large-scale phosphoproteome 
studies on the effect of metformin on primary human skeletal muscle cells have 
been reported. 
In the present study, we performed the first large scale differential 
phosphoproteome analysis of primary skeletal muscle cells derived from 
obese/overweight insulin resistant non-diabetic participants under various 
conditions (with/out metformin treatment) by a combination of phosphopeptide 
enrichment technique, Titanium dioxide (TiO2), and the Universal-SILAC 
approach recently developed in our laboratory [47].   The goal of the study is to 
determine effect of metformin on global phosphorylation profiles in insulin 
resistant primary skeletal muscle cells with the emphasis on kinases and/or 
phosphatases that may be regulated by metformin. 
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CHAPTER 2 RESEARCH DESIGN AND METHODS 
This project involves clinical study and proteomics study. In clinical study, 
after successful phone screening with participants, the clinical visit was 
scheduled. The research consent form was explained to them in detail during 
visit-1 and screening tests were performed to check their eligibility for the study 
(following the IRB protocol). After a thorough review by physicians, eligible 
participants were scheduled for the in-patient clinical test (visit-2) in which 
hyperinsulinemic-euglycemic clamp and skeletal muscle biopsy were performed 
and tissue sample of skeletal muscle from the thigh were collected and was used 
to perform primary cell culture. The cultured skeletal muscle cells were treated 
with different conditions. Cells were harvested and collected to perform 
proteomics study. Proteomics experiments started with spike-in standards (stable 
isotope labeled protein lysates obtained by stable isotope labeling with amino 
acids in cell culture (SILAC)) to minimize experimental variation, followed by in-
solution trypsin digestion to generate tryptic peptides, TiO2 to enrich 
phosphorylated peptides, and mass spectrometry to identify and quantify 
phosphorylation sites using the Universal-SILAC approach recently developed in 
our laboratory [47] (See Figure 8A). 
2.1 MATERIALS 
2.1.1 REAGENTS 
 For the primary cell culture, Dulbecco’s Modified Eagle Medium (including 
dialyzed DMEM), Phosphate Buffer Saline, Fetal Bovine Serum (including 
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dialyzed FBS), isotopes for labeling aspect were purchased from Thermo Fisher 
(Fair Lawn, NJ). Sequencing grade trypsin was purchased from Promega 
(Madison, WI). Metformin-hydrochloride was purchased from Sigma- Aldrich (St. 
Louis, MO) and TiO2 beads were purchased from GL Sciences (Tokyo, Japan). 
2.2 SUBJECTS 
 Four overweight or obese participants were recruited for clinical research 
study. The motive and possible risks were explained in detail to all participants. 
The research consent form which was approved by the Institutional Review 
Board of Wayne State University was described thoroughly and signed by 
participants for further participation in the study. After going through vitals, bio-
impedence test, electrocardiogram (ECG), and urine test, the Oral Glucose 
Tolerance Test (OGTT) was performed. In the OGTT, a sugar drink containing 75 
g of sugar was given to the participant to determine their glucose tolerance. 
Figure 5 describes how the group of participant had been selected. None of the 
participants had any medical problems or any other issues that might affect the 
research results including any heavy exercises. All participants were asked not to 
perform any kind of exercise for at least two days before the OGTT. Participants 
were asked to fast for at least 10 hours before the OGTT. 
2.3 HYPERINSULINEMIC-EUGLYCEMIC CLAMP  
 To determine or measure insulin sensitivity, hyperinsulinemic- euglycemic 
clamp study was performed [4]. Participants were asked to fast overnight for at 
least 10 hours. The study began in the morning at around 8:30 am. After taking 
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vitals, a catheter was inserted in an antecubital vein and maintained during the 
study for the infusion of insulin and glucose. A second catheter was inserted in a 
vein in the contra lateral arm for sampling blood to measure glucose level. The 
arm was covered with a heating pad (120°F or 48.89°C). At 9 am, skeletal 
muscle tissue samples from the vastus lateralis of human subjects were obtained 
through standard biopsy procedure using lidocaine as a local anesthetic agent. 
The collected samples (basal samples) of skeletal muscle were immediately 
washed with saline containing protease inhibitors and were used for primary cell 
culture immediately. Infusion of insulin and glucose was started at 9:30 am and 
kept constant up to 2 hours (120 minutes). Infusion of human regular insulin 
(Humulin R; Elily, Indianapolis, IN) was started at the rate of 80 mU m-2 minute-
1. Infusion of 20% d-glucose was started simultaneously and adjusted the 
infusion to maintain the blood sugar level of 90 mg/dl. After 120 minutes, another 
biopsy was performed at contralateral vastus lateralis muscle. Samples of 
skeletal muscle were washed using the same saline and protease inhibitor 
solution as before and primary cell culture was performed. Overall procedure of 
hyperinsulinemic-euglycemic clamp is shown in Figure 6. 
2.4 PROTEOMICS EXPERIMENTAL PROCEDURES 
2.4.1 PRIMARY CELL CULTURE 
 Human Skeletal Muscle (HSkM) biopsies were washed twice with 
Phosphate Buffer Saline (PBS) (from Glibco) with careful handling. The HSkM 
tissues were placed in petri plate and washed with PBS. HSkM tissues were cut 
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into small or fine pieces using sterilized scissors. The cut tissues were 
transferred to 50 ml tube with PBS and allowed to settle down. Supernatant was 
removed without disturbing tissues. Trypsin with the concentration of 0.05 
(mg/ml) was added and kept in a water bath for one hour with shaking every 10 
minutes. Meanwhile, the growth media for cells was prepared. Growth media was 
prepared using 0.22 µm filter units in sterilized condition (under the hood). Fetuin 
(50 µg/ml), dexamethasone (0.4 µg/ml), Endothelial Growth Factor (EGF) (10 
ng/ml), sodium pyruvate (1%), Non-Essential Amino Acids (NEAA) (1%), 
Penicillin-Streptomycin-Glutamine (PSG) (1%), Fetal Bovine Serum (FBS) (20%) 
was added to Dulbecco’s Modified Eagle Medium (DMEM) (from life 
technologies). Tubes containing HSkM tissues were centrifuged at the speed of 
1000 rpm for 5 min and allowed cells to settle down. The supernatant from tubes 
were removed under the hood and 10 ml of growth media was added to the 
tubes. Using filter units, it was transferred to 55 mm2 petri dishes after pipetting 
up and down several times. Maintenance and splitting of cells were 
accomplished until each cell line reached to six 150 mm large culture dishes.  
Each cell line was treated with six different conditions: 1) without 
metformin treatment and without 15 minutes insulin stimulation (No_Met_BAS), 
2) without metformin treatment and with 15 minutes insulin stimulation 
(No_Met_INS), 3) with 1 day low metformin treatment (50 µM) and without 15 
minutes insulin stimulation (Low_Met_BAS), 4) with 1 day low metformin 
treatment (50 µM) and with 15 minutes insulin stimulation (Low_Met_INS), 5) 
15 
 
 
 
with 1 day high metformin treatment (800 µM) and without 15 minutes insulin 
stimulation (high_Met_BAS), 6) with 1 day high metformin treatment (800 µM) 
and with 15 minutes insulin stimulation (high_Met_INS). Lysis buffer was used to 
collect the cell lines. Lysis buffer was made up of 50 mM HEPES (pH 7.6), 150 
mM NaCl, 20 mM sodium pyrophosphate, 10 mM NaF, 20 mM beta-
glycerophosphate, 1% Triton in required amount of HPLC grade water including 
protease inhibitors such as 1% leupeptin, 1% aprotinin, 1mM sodium vanadate, 1 
mM PMSF.  
2.4.2 BRADFORD PROTEIN MEASUREMENT 
 Cell lysates were centrifuged at 4°C, 13,000 rpm for 10 minutes followed 
by homogenizing lysates for 10 minutes. Protein concentrations from the lysates 
were fractioned out for measurement. Protein concentrations were determined 
through Bradford Protein Assay (Bio-Rad, Hercules, CA) using BSA as the 
standard [48]. 
2.4.3 PROTEIN DIGESTION 
 Protein from each sample was mixed with SILAC protein sample in a 4:1 
ratio. Protein with 1.5 mg amount from each sample was mixed with 0.375 mg of 
SILAC protein and further used for protein digestion and TiO2 phosphopeptide 
enrichment experiment. The total amount of protein in each sample was 1.875 
mg. DTT was added to each sample in the final concentration of DTT would be 
50 mM and kept in hot-bath at 95°C for 5 min. After 10 min, IDA was added to 
each sample in the final concentration of 150 mM and kept in dark for 30 
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minutes. Each sample was filtered at speed of 13,000 rcf, 4°C temperature in 
centrifugation using 1.5 µm Amicon filter units after shaking on vertex shaker. 
Pellets were also washed twice with 200 µL of 40 mM Ammonium Bicarbonate 
(ABC). Amicon filter units were reversed in fresh tubes and centrifuged at speed 
of 10,000 rcf, 4°C temperature for 2 minutes to collects the pellets. The pellets 
were dissolved using 500-1000 µL of ABC. Trypsin was added to each sample at 
1:100 ratio and kept on shaker with 800 rpm speed at room temperature. Trypsin 
with the same concentration was added to each sample again after 4 hours and 
kept on the shaker with 350 rpm speed at room temperature overnight. The next 
day, each sample was filtered using 1.5 µm Amicon filter units. The filtrate was 
saved. The filter units were washed twice with 100 µL ABC and filtrates saved. 
All filtrate for each sample was combined. Filtrate was evaporated till complete 
dryness, but not over dried. 
2.4.4 TITANIUM DIOXIDE PHOSPHOPEPTIDE ENRICHMENT 
 The phosphopeptides were enriched using Titanium dioxide (TiO2) beads 
essentially as described elsewhere with some modifications [49, 50]. Briefly, the 
TiO2 beads (GL Sciences, Tokyo, Japan) were mixed with 200 μL 65% ACN, 2% 
TFA with saturated by glutamic acid for 15 min. The peptide samples were then 
mixed with TiO2 beads and incubated with gentle rotation for 30 min. The 
incubated beads were then washed with 65% ACN, 0.5% TFA twice and 
65%ACN, 0.1% TFA twice. The bound peptides were eluted once with 300 mM 
NH4OH, 50% ACN and twice with 500 mM NH4OH, 60% ACN. The eluates were 
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dried down by vacuum centrifugation and reconstituted in 0.1% TFA for MS 
analysis. The experimental flow chart is shown in Figure 8A and 8B. 
2.4.5 HPLC-ESI-MS/MS ANALYSIS 
 The peptide mixture was separated with a linear gradient of 5-35% buffer 
B (100% ACN and 0.1% FA) in 180 minutes at a flow rate of 250 nL/min on a C-
18-reversed phase column (75µm ID, 15 cm length) packed in-house with 
ReproSil-Pur C18-AQ µm resin (Dr. Maisch GmbH) in buffer A (0.1% FA). A 
nanoflow Ultimate 3000 RSLCnano system (Thermo Scientific) was on-line 
coupled to a Thermo Finnigan LTQ-Orbitrap Elite fitted with a nanospray flex Ion 
source (Thermo Fisher, San Jose, CA). MS data were acquired in a “Top-20-
RCID” data-dependent strategy selecting the fragmentation events based on the 
precursor abundance in the survey scan (400-1650 Th). 
2.4.6 PHOSPHOPEPTIDE IDENTIFICATION 
 Peptides/protein identification and quantification were performed using the 
MaxQuant, one of the popular quantitative proteomics software packages [51, 
52].  Briefly, raw MS files were processed using the MaxQuant (ver.1. 3.0.5) 
against a database with forward and reversed Uniprot Human protein sequences, 
downloaded from www.uniprot.org.  Standard settings in the MaxQuant were 
applied.  Parent mass tolerance was 5 p.p.m., and fragment mass tolerance was 
0.5 Da. Two missing trypsin cleavage site was allowed, carbamidomethylation 
was searched as a fixed modification, and methionine oxidation (Mox), 
phosphorylation (STY), Acetylation (Protein N-term), isotope-labeled lysine 
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(+4.00 Da) and isotope-labeled arginine (+10.00 Da) were allowed as a variable 
modification. The FDR for both proteins and peptides (with minimum 6 amino 
acids) was set to 0.01.  Only phosphorylation sites with a localization probability 
greater than 0.75 (classified as class I phosphosites, a commonly used threshold 
in phosphoproteome studies [53, 54]) were considered. 
2.4.7 PHOSPHOPEPTIDE QUANTIFICATION 
 To minimize the experimental variation during sample preparation and 
HPLC-ESI-MS/MS data acquisition, we have developed and validated a modified 
Super-SILAC approach, in which SILAC labeled protein lysates were spiked-in to 
each experimental sample and were used as an universal standard for 
quantification purpose [47]. This modified Super-SILAC approach (we now term it 
as Universal-SILAC) provides quantitative information for more phosphorylation 
sites than the traditional Super-SILAC quantification. Using this approach, we 
identified 3876 phosphorylation sites (620 were novel), and found that 
knockdown of Protein phosphatase 1 regulatory subunit 12A in L6 cells resulted 
in increased overall phosphorylation in L6 cells at the basal condition, and 
changed phosphorylation levels for 698 sites (assigned to 295 phosphoproteins) 
at the basal and/or insulin-stimulated conditions [47].  In the present study, we 
applied Universal-SILAC to the quantification of the phosphoproteome in primary 
skeletal muscle cells derived from overweight/obese human participants in the 
absence and presence of metformin, and calculated the modified SILAC ratio as 
described in our manuscript [47]: an individual peak area for a phosphorylation 
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site (PAi) was normalized against the sum of the peak area for the heavy labeled 
phosphorylation sites in the same sample: 
Norm: ݅ ൌ PA݅Sum	of	the	peak	area	for	the	heavy	labeled	phosphorylation	sites			 
 The normalized peak area (i.e., modified SILAC ratio) for each 
phosphorylation site was log2 transformed and compared to assess effects of 
insulin or metformin on phosphorylation levels among the 6 sets of samples (as 
described 6 different conditions above: No_Met_BAS, No_Met_INS, 
Low_Met_BAS, Low_Met_INS, high_Met_BAS, and high_Met_INS) of primary 
skeletal muscle cells derived from muscle biopsies from 4 obese/overweight 
human participants. 
2.4.8 STATISTICAL ANALYSIS 
 Although a large number of phosphorylation sites were assigned in at 
least one of the 24 samples that were studied, a series of filters were used to 
narrow the number of phosphorylation sites that were used in comparisons 
among groups as described in Figure 9.  Statistical significance was assessed 
using paired t tests. Differences were considered statistically significant at 
p<0.05.  
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CHAPTER 3 RESULTS 
 As can be seen from Table 1, four participants were included for the 
phosphorylation study including 2 male and 2 female. Body Mass Index (BMI) 
and M-values indicate that they were obese/overweight and insulin resistant. 
Other parameters such as Fasting Blood Sugar (FBS) levels, 2 hour OGTT 
values, and HBA1c values confirmed that they are not diabetic. 
Phosphoproteomics analysis of primary skeletal muscle cells derived from 
muscle biopsies from 4 obese/overweight human participants identified 2930 
phosphorylation sites assigned to 1085 proteins.  
Among 2930 phosphorylation sites, 750 sites were identified in more than 
half of the 24 samples (i.e. more than 12 samples).  Among the 750 sites, 325 
sites showed significant changes among the 6 sets of samples, including 6 sites 
in 4 phosphatase subunits and 17 sites in 9 kinases subunits which are showed 
in Table 3.  
21 
 
 
 
CHAPTER 4 DISCUSSION 
 After performing proteomics experiments on cells from primary cell culture, 
we found 325 phosphorylation sites which showed significant changes upon 
metformin treatment and/or insulin stimulation. Among 325 phosphorylation sites, 
we focused on 6 phospho sites in 4 phosphatase subunits and 17 
phosphorylation sites in 9 kinase subunits as described in table 3. Few research 
studies have been reported on these phosphorylation sites for metformin studies. 
Protein Phosphatase inhibitor 2 restrains the catalytic subunit of protein 
phosphatase 1 [55]. phosphatase inhibitor-2 (S121) is regulated/ phosphorylated 
by Casein Kinase-2 (CK2) [55]. Phosphorylation is necessary for the regulation at 
T73 or T72 by Glycogen Synthase Kinase-3 (GSK-3) in human spermatozoa [55] 
and COS-7 cells (kidney cells from monkeys) [55], respectively. Phosphorylation 
at S121, S120, S86 and T72/T73 is necessary for the localization of protein 
phosphatase inhibitor-2 during S phase of mitosis [56]. Moreover, research has 
been reported on S121 phosphorylation using hepatic cell lines, renal cell lines, 
lymphocytes, spermatozoa, cancer and leukemia cell lines, but not skeletal 
muscle tissue or cells. In our experiment, S121 phosphorylation has shown 
significant change. S121 phosphorylation was higher in cells treated with both 
low and high metformin compared to no metformin under insulin stimulation.  In 
addition, S122 phosphorylation was higher in cells treated with high metformin 
compared to no metformin under insulin stimulation (See Figure 10A and 10B). 
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 PPP2R5E (S33 and S34) (PP2A R epsilon subunit) & PPP2R5D (S88) 
(PP2A R delta subunit) are a subfamily of PP2A Protein Phosphatase 2A). PPP2 
(or PP2A) accounts for almost 80% of serine/threonine Phospho Protein 
Phosphatases (PPP) in mammalian cells and considered to be involved in most 
of the serine/threonine phosphatase activity in cells. PP2A is a trimeric 
holoenzyme consists of three subunits, scaffold A subunit, catalytic C subunit 
and regulatory B subunit [57]. In mammals, the function of catalytic subunit is 
dephosphorylation. There are several families of the B subunit which are 
believed to be involved in stabilization of holoenzyme via binding with the A or C 
subunit. The B subunit is felt to be involved in regulation of the A or C subunit for 
its further activities [58]. The δ form of B subunit is expressed in cytoplasm and 
nucleus where ε form is expressed in cytoplasm only [58]. Nuclear form may be 
involved in regulation of transcription by CREB and AP-1, in controlling the 
activity of the retinoblastoma proteins and in the dephosphorylation of p53 [58, 
59].  The B regulatory subunit is believed to be involved in modulations of 
substrate selectivity and catalytic activity [59]. The B subunit is involved in cell 
growth and apoptosis [57]. For all three specified phosphorylation sites, no 
studies on their role in skeletal muscle cells have been reported. Significant 
changes that are observed in our experiment in comparison with different 
treatment has been shown in Figure 12A, 12B and 12C in S88, S33 and S34 
sites, respectively. 
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 PPP1R12A (Protein Phosphatase 1 regulatory subunit 12A) (S299) - 
Studies for this particular site has been reported for cancer but not for any other 
diseases in human.  It has never been studied in human skeletal muscle tissue or 
cells before. It has been found that PPP1R12A and the catalytic subunit of PP1 
(PP1cδ) were identified as interaction partners of IRS-1 in L6 cells [60]. 
PPP1R12A/PP1cδ may dephosphorylate IRS-1 in L6 cells to maintain proper 
insulin action through IRS-1. The kinases and phosphatase has effect on p85 
[60]. Observed significant changes in phosphor-S299 in the experiment have 
been shown in Figure 11. 
 DCLK1 or doublecortin-like kinase 1(4 isoforms) is a serine-threonine 
kinase of the calmodulin kinase (CAMK) family. There are 6 phosphorylated sites 
were observed on serine/threonine protein kinase DCLK1 at S330, S334, T336, 
S337, S353, S362. Most of the research on DCLK1 within human and other 
vertebrates has been done on nervous tissue, which is primarily thought to be 
involved in cell differentiation and neurogenesis. DCLK1 has been shown to 
interact with calmodulin 1 (CALM1), doublecortin (DCX), and tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase activation protein (YWHAE) in 
mouse brain [61, 62]. Phosphorylation of DCLK1 S330, S334, T336, S337, S353, 
S362/3 have been identified in multiple cell types including embryonic stem cells 
[63-65] or in brain tissue; thus, this is the first identification of these 
phosphorylation sites within skeletal muscle cells as well as associated with 
insulin resistance in human or any other organism. Notably, DCLK1 along with 
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multiple phosphorylation sites observed here have been detected in mouse 
cardiac muscle [66].  However, the role of DCLK1 in skeletal muscle and/or 
insulin signaling is yet to be determined. Phosphorylation of S330, S334, S337, 
was observed in 3T3-L1 adipocytes upon insulin stimulation [67]; however, the 
regulation of these phosphosites have not been studied. All of the 
phosphorylation sites of DCLK1 observed within this study fall between the 2nd 
doublecortin domain and the protein kinase domain, which suggests 
phosphorylation may regulate the binding of DCX and/or kinase 
activity/specificity. Figure 13A, 13B, 13C, 13D, 13E, and 13F reflects 
phosphorylation sites in DCLK1 with different treatment comparison for S330, 
S334, T336, S337, S353 and S362 sites, respectively. 
 Serine/threonine-protein kinase or p21-activated kinase (PAK4, S181). 
PAK4 is regulated by Rho GTPase activity during cytoskeletal reorganization and 
nuclear signaling in apoptosis and cell cycle regulation [68].  PAK4 has been 
shown to interact with, but not limited to, CDC42, CAS8, and GRB2; known 
substrates of PAK4 include LIM kinase, Slingshot phosphatase, GEF-H1, Integrin 
beta 5, BAD, Myosin light chain 9, Ran, Paxillin, Raf-1, Beta-Catenin, p120-
Catenin, and PDZ-RhoGEF [69].  Within humans and rodents, S181 has been 
identified within multiple cancer-related cell types but not within skeletal muscle 
cells. The role of S181 is unknown but may regulate auto inhibition, kinase 
activity or binding of GTPase.  Phosphorylation of S181 was observed in 3T3-L1 
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adipocytes upon insulin stimulation [67]. Figure 14 illustrated significant changes 
in phosphor-S181 in PAK4 upon metformin and insulin treatment. 
Phosphatidylinositol 4-kinase type 2-alpha (PI4K2A, S47 and S51) 
PI4K2A has been shown to interact with and promote VAMP3, part of the 
SNARE complex with GLUT4 involved in glucose uptake [70].  Phosphorylation 
of S47 and S51 was observed in 3T3-L1 adipocytes upon insulin stimulation [67].  
S47 and S51 have not been mutated and don’t fall within any well-defined 
domain. PI4K2A S47 and S51 phosphorylation has never been studied for 
skeletal muscle cells before. Figure 15A and 15B shows significant changes in 
S47 and S51 phosphorylation, respectively. 
5'-AMP-activated protein kinase subunit beta-1 (PRKAB1, S108) and 5'-
AMP-activated protein kinase subunit beta-2 (PRKAB2, S108) also known as 
AMPK. S108 site on both proteins has been observed as phosphorylated. AMPK 
contains three subunit, alpha, beta and gamma. There are different mechanisms 
of metformin have been proposed for its effect on AMPK. It has been proposed 
that metformin primarily affects hepatic glucose production through activating 
AMPK but our results support its effect in skeletal muscle also. It has been found 
that metformin has effect on alpha subunit of AMPK but effect on beta subunits of 
AMPK has been observed in our study. In liver AMPK is expected to be involved 
in reducing glucose production but in skeletal muscle is involved in glucose 
uptake. Research study also suggests that AMPK has an effect on alpha subunit 
of AMPK [30]. No research study has been done on PRKAB1 (S108) and 
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PRKAB2 (S108) for diabetes study using skeletal muscle. Significant increase of 
S108 phosphorylation in PRKAB1 (AMPK-beta-1) and PRKAB2 (AMPK-beta-2) 
upon high metformin treatment is shown in Figure 16 and 17 respectively. 
cAMP-dependent protein kinase type-II alpha regulatory subunit 
(PRKARA2, S78 and S80).  Activated PRKARA2 binds to four cAMP molecules. 
Research on S78 and S80 phosphorylation has been reported on pulmonary cell 
lines, skeletal muscle, liver, spermatozoa, stem cells but regulation of S78 and 
S80 phosphorylation for metformin has not been reported. Figure 18A and 18B 
shows the significant changes in PRKARA2 S78 and S80 phosphorylation in our 
experiments. 
Protein kinase PRP4 homolog (S277).  More study for this phospho site 
has been done on different types of cancer but study on skeletal muscle has not 
been reported yet and also it has not been studied for metformin’s action. Figure 
19 shows the significant change in this phosphorylation site in our experiments. 
Protein kinase-10 (STK10, S450 and S454). STK10 is a kinase from 
STE20 family. Kinases from STE20 family are important in cellular functions such 
as apoptosis and morphogenesis. STK10 has an effect on PIK1 (Polo-like kinase 
kinase). STK10 is believed to be involved in phosphorylation of PIK1 [71]. It is 
mostly expressed in hematopoietic tissues. Functions of STK10 in human is 
more complex than in mice [71]. Site specific regulation study has not been 
performed in skeletal muscle and/or for metformin. Figure 21A and 21B show 
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significant changes in S450 and S454 phosphorylation in our experiments, 
respectively. 
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CHAPTER 5 CONCLUSION & FUTURE STUDIES 
 In summary, we report the 1st global analysis of the effect of metformin on 
phosphorylation profiles in primary skeletal muscle cells derived from muscle 
biopsies from 4 obese/overweight insulin resistant human participants. We 
identified 2930 phosphorylation sites assigned to 1085 proteins.  More 
importantly, 325 sites showed significant changes among the 6 sets of samples, 
including 6 sites in 4 phosphatase subunits and 17 sites in 9 kinases/kinase 
subunits (Table 3). We demonstrated that metformin has significant effect on 
some of the phospho sites present in phosphatases and kinases which are 
important for insulin signaling or glucose uptake. We also noticed that there is 
very little known about the involvement of these 23 phosphorylation sites in the 
development of diabetes or in the action of metformin, because of few reported 
site-specific regulation studies. These results may shed new lights into molecular 
mechanisms for metformin’s action.  
 We will perform literature search on the other phosphorylation sites with a 
significant changes among the 6 sets of samples. In addition, we will quantify the 
total corresponding protein abundance through western blot and/or through 
HPLC-ESI-MS/MS.  Moreover, we will perform the same experiments in primary 
cell culture from lean/healthy and T2D people to identify metformin stimulated or 
suppressed phosphorylation sites.  Furthermore, we will use a variety of 
techniques, such as site-specific mutagenesis, in vitro kinase assays, in cell 
kinase inhibitor assays, as well as the generation of several phospho-specific 
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antibodies to study the biological function of novel phosphorylation sites 
regulated by metformin. 
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Table 1. Clinical characteristics of participants in the metformin study. 
Results were shown as mean ± SEM values. 
 4 Participants in OB/OW group 
Gender (M/F) (2/2) 
Age (years) 36 ± 9.7 
BMI (kg/m2) 29.7 ± 2.8 
FBS (mg/dl) 92.72 ± 2.3 
2h OGTT (mg/dl) 149.6 ± 20.6 
HBA1c (%) 5.4 ± 0.1 
M values (mg/kg/min) 4.2 ± 0.8 
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Table 2. Different conditions and/or treatments of cells 
 
Sr. No. 
Condition/ Treatment 
(No insulin stimulation) 
1 Low Glucose + No Metformin (3d) 
2 Low Glucose (2d) + Low Metformin (1d) 
3 Low Glucose (2d) + High Metformin (1d) 
With 15 minutes insulin stimulation 
4 Low Glucose + No Metformin (3d) 
5 Low Glucose (2d) + Low Metformin (1d) 
6 Low Glucose (2d) + High Metformin (1d) 
 
 
The above table describes the conditions that are cells treated with. Each 
condition was treated with 15 minutes insulin stimulation and without insulin 
stimulation. 
1d- 1 day, 2- 2 day, 3d- 3 day 
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Table 3. Significantly changed phospho sites among the 6 sets of samples 
Protein names Protein IDs Gene names 
Phosphorylation 
site 
 
PHOSPHATASE SUBUNITS 
Protein phosphatase 
inhibitor 2 
P41236 PPP1R2 S121 
Protein phosphatase 
inhibitor 2 
P41236 PPP1R2 S122 
Protein phosphatase 
1 regulatory subunit 
12A 
O14974 PPP1R12A S299 
Serine/threonine-
protein phosphatase 
2A 56 kDa regulatory 
subunit delta isoform 
Q14738 PPP2R5D S88 
Serine/threonine-
protein phosphatase 
2A 56 kDa regulatory 
subunit epsilon 
isoform 
Q16537 PPP2R5E S33 
Serine/threonine-
protein phosphatase 
2A 56 kDa regulatory 
subunit epsilon 
isoform 
Q16537 PPP2R5E S34 
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KINASES/KINASE SUBUNITS 
Serine/threonine-
protein kinase DCLK1 
Q5VZY9 DCLK1 S330 
Serine/threonine-
protein kinase DCLK1 
Q5VZY9 DCLK1 S334 
Serine/threonine-
protein kinase DCLK1 
Q5VZY9 DCLK1 T336 
Serine/threonine-
protein kinase DCLK1 
Q5VZY9 DCLK1 S337 
Serine/threonine-
protein kinase DCLK1 
Q5VZY9 DCLK1 S353 
Serine/threonine-
protein kinase DCLK1 
Q5VZY9 DCLK1 S362 
Serine/threonine-
protein kinase PAK 4 
O96013 PAK4 S181 
Phosphatidylinositol 
4-kinase type 2-alpha 
Q9BTU6 PI4K2A S47 
Phosphatidylinositol 
4-kinase type 2-alpha 
Q9BTU6 PI4K2A S51 
5'-AMP-activated 
protein kinase subunit 
beta-1 
Q9Y478 PRKAB1 S108 
5'-AMP-activated 
protein kinase subunit 
beta-2 
O43741 PRKAB2 S108 
cAMP-dependent 
protein kinase type II-
alpha regulatory 
P13861 PRKAR2A S78 
34 
 
 
 
subunit 
cAMP-dependent 
protein kinase type II-
alpha regulatory 
subunit 
P13861 PRKAR2A S80 
Serine/threonine-
protein kinase PRP4 
homolog 
Q13523 PRPF4B S277 
Serine/threonine-
protein kinase SIK3 
H0Y4E8 SIK3 S545 
Serine/threonine-
protein kinase 10 
O94804 STK10 S450 
Serine/threonine-
protein kinase 10 
O94804 STK10 S454 
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DETERMINATION OF DIABETES & PRE-DIABETES
IF FBS:           
NORMAL <5.7
PRE-DIABETIC 
5.7-6.5
DIABETIC  
>6.5
OGTT 
AT 2 HRS, IF:
NORMAL
<100mg/dl
PRE 
DIABETES
<126mg/dl
>100 mg/dl
DIABETES
>126mg/
dl
Diabetes Care January 2014 vol. 37 no. Supplement 1 S81‐S90 
IF HBA1c:
 
 
Figure 5. Parameters with their range to determine diabetes & pre-diabetes. 
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Figure 6. Hyperinsulinemic-euglycemic clamp  
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Biopsy samples from 4 participants 
Primary cell culture 
Cells treated with 6 different conditions 
(with and without metformin, and/or 15 
min insulin stimulation) 
Total 24 sample of cells with treatment 
from primary cell culture 
Mixed with SILAC 
 (Protein 4:1 SILAC) 
Trypsin digestion and following steps 
Figure 8B. Sample preparation for proteomics experiments 
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  Total 24 samples were analyzed
2,930 total phosphorylation sites were 
identified among all 24 samples 
750 phosphorylation sites were present in 
more than 50% of samples (in >12 samples) 
325 phosphorylation sites showed significant 
change  
23 phosphorylation sites were selected based 
on our interest  
Includes 6 phosphorylation sites from 4 
phosphatase subunit and 17 
phosphorylation sites from 6 kinases 
       Figure 9. The statistical proteomics analysis workflow 
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ABSTRACT 
EFFECT OF METFORMIN ON GLOBAL PHOSPHORYLATION PROFILES OF 
PRIMARY SKELETAL MUSCLE DERIVED FROM OVERWEIGHT/OBESE 
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 Metformin is a drug from the biguanide class and it has been in use for the 
treatment of type 2 diabetes for a long time, and it can improve insulin sensitivity 
in skeletal muscle. However, the mechanism for metformin’s action is unclear. 
Phosphatases and kinases, and their subunits are the proteins required for 
dephosphorylation and phosphorylation of proteins in cells during various 
signaling pathways. Phosphorylation studies of proteins from primary cell culture 
derived from skeletal muscle tissue from obese/overweight insulin resistant 
participants will help to understand the regulation of phosphorylation in 
phosphatases and kinases by metformin. 
 In the current research, we used primary cell culture cells of human 
skeletal muscle tissue to identify and quantify the phosphorylation effects of 
metformin in obese/overweight participants. After treating cells with different 
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conditions which include different concentration of metformin, we identify 2930 
phospho sites in 1085 proteins. Among 2930 phospho sites, 325 phospho sites 
showed significant change among 6 sets of samples (total 24 samples). Of 
particular interest, metformin treatment significantly changed phosphorylation 
levels of 23 sites including 6 phosphorylation sites in 4 phosphatase subunits and 
17 phosphorylation sites in 9 kinases/kinase subunits.  These results provide 
new information on how metformin works in skeletal muscle cells. 
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